Gilead still eyeing cancer, inflammation deals

Gilead Sciences Inc. (NASDAQ:GILD) reported earnings that showed a continued reliance on HCV sales and company executives expressed interest in dealmaking to broaden Gilead's cancer and inflammatory portfolios.

"It's pretty clear we have to do additional partnerships or find additional avenues to broaden the revenue stream," President and COO John Milligan told a conference call Tuesday, adding that the market has "shifted dramatically in our favor for doing those sorts of partnerships." Last week, the company promoted Milligan to CEO, effective March 10 (see BioCentury Extra, Jan. 29). ...